Growth & profitability
- Revenue has declined 28.4% per year over the past 3 years.
- Net income has grown faster than revenue (-13.8% vs -28.4% per year).
- Operating margin has expanded, at 66.7% in the latest year.
NNNN Financials Anbio Biotechnology
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $9M | $6M | 87.2% | 66.7% | — | — | $8M |
| 2024 | $8M | $2M | 71.9% | 24.4% | — | — | $12M |
| 2023 | $7M | $2M | 50.1% | 29.2% | — | — | $10M |
| 2022 | $24M | $10M | 53.4% | 43.3% | — | — | — |
Valuation over time
How the market has priced NNNN against its own fundamentals since 2025-02 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 122.9× (Feb '25) to 109.5× (Jun '26).
- The price-to-sales ratio has risen from 35.6× (Feb '25) to 81.1× (Jun '26).
P/E
P/S
Frequently asked questions
Is NNNN growing its revenue and profit?
Over the past 3 years, Anbio Biotechnology's revenue has declined 28.4% per year, and net income declined 13.8% per year. These are computed facts, not advice.
How much debt does NNNN have?
As of FY2025, Anbio Biotechnology reported — of total debt against $8M of cash.
What is NNNN's profit margin?
In FY2025, gross margin was 87.2%, operating margin 66.7%, and net margin 74.1%.
What is NNNN's P/E ratio?
As of Jun '26, Anbio Biotechnology traded at a price-to-earnings ratio of about 109.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.